Drugs / CV7202
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03713086 | Oct 2018 → Nov 2021 | rabies | CureVac | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CV7202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03713086 ↗ |
| Modality | Messenger RNA (mRNA) | “Following successful preclinical studies with mRNA encapsulated in lipid nanoparticles (LNP), we tested an mRNA-LNP formulation (CV7202).” PMID 33487468 ↗ Jan 2021 |
| Route | Intramuscular | “intramuscular injections” PMID 33487468 ↗ Jan 2021 |